The Cancer Research Institute awarded $28.5 million to scientists at 43 institutions in 8 countries who are advancing lifesaving research in immunology and cancer immunotherapy during its 2021 funding cycle.
This 9th annual Cancer Immunotherapy Month™, CRI aims to help close the information and research gap to better serve the Hispanic community in the United States.
Cancer Research Institute celebrates progress in cancer immunotherapy research, announces new initiatives aimed at addressing racial and ethnic disparities in cancer treatment and academic research, during ninth annual Cancer Immunotherapy Month this June.
First study to test RevImmune’s IL-7 drug candidate in cancer patients infected with the SARS-CoV-2 coronavirus at increased risk of progressing to severe stages of COVID-19
Combination drug strategies gain ground in global immuno-oncology pipeline of PD-1 and PD-L1 clinical trials, new report from Cancer Research Institute reveals.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.